Elemer Piros (Lucid Capital) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Elemer Piros's stock ratings?

About 44% of Elemer's ratings were profitable over a one-year hold, with an average return of +6.8% per rating, measured by 13Foresight from historical prices.

Q: How is Elemer ranked?

Elemer Piros is ranked #2416 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Elemer Piros

LUCI

Elemer Piros

Lucid Capital

Wall Street Analyst

★☆☆☆☆

#2416

on 13Foresight · ranked by our own returns

44%

Success Rate

+6.8%

Average Return

23 of 52 calls profitable · -6.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 44% of Elemer Piros's ratings turned a profit when each position was held for 1 year — averaging +6.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

20 Buy 5 Hold 1 Sell

Elemer's Stock Coverage 61 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ADIL Adial Pharmaceuticals	Jun 15, 2026	BUY	Strong Buy +1855.2% avg upside 6 analysts	$6.00 130.75% Upside	·
NRXP NRX Pharmaceuticals	May 13, 2026	BUY	Strong Buy +912.6% avg upside 5 analysts	$49.00 1134.19% Upside	+30.2%
XOMA XOMA Royalty Corporation	Apr 27, 2026	HOLD	Buy -46.4% avg upside 11 analysts	$39.00 6.81% Downside	-0.7%
PASG Passage Bio	Apr 20, 2026	HOLD	Buy +214.0% avg upside 14 analysts	$9.00 61.05% Upside	-18.1%
NGEN NervGen Pharma	Apr 15, 2026	BUY	Strong Buy +359.2% avg upside 8 analysts	$18.00 718.10% Upside	-50.9%
OCGN Ocugen	Mar 11, 2026	BUY	Strong Buy +646.0% avg upside 17 analysts	$22.00 1674.15% Upside	-43.5%
INMB Inmune Bio	Mar 11, 2026	BUY	Buy +753.7% avg upside 11 analysts	$9.00 520.68% Upside	-12.7%
QNCX Quince Therapeutics	Jan 30, 2026	SELL	Hold +2771.2% avg upside 13 analysts	—	+36.8%
MNOV Medicinova	Jan 05, 2026	BUY	Strong Buy +460.6% avg upside 5 analysts	$11.00 733.42% Upside	-0.7%
VTGN VistaGen Therapeutics	Dec 17, 2025	HOLD	Hold +287.9% avg upside 8 analysts	$1.00 49.17% Upside	-30.2%
CH:NWRN Newron Pharmaceuticals SpA	Dec 11, 2025	BUY	Strong Buy +262.4% avg upside 3 analysts	—	·
NEUP Neuphoria Therapeutics	Oct 21, 2025	HOLD	Strong Buy +365.8% avg upside 6 analysts	$2.30 46.54% Downside	-2.5%
FLNA Filana Therapeutics	Oct 06, 2025	BUY	Buy +2987.5% avg upside 4 analysts	$8.00 555.80% Upside	·
COYA Coya Therapeutics, Inc.	Sep 22, 2025	BUY	Strong Buy +225.2% avg upside 7 analysts	$20.00 306.56% Upside	-14.6%
OVID Ovid Therapeutics	Aug 13, 2025	BUY	Strong Buy +108.4% avg upside 17 analysts	$5.50 142.20% Upside	+206.5%
OKYO OKYO Pharma Limited Sponsored ADR	Jul 31, 2025	BUY	Strong Buy +404.5% avg upside 4 analysts	$13.00 717.57% Upside	-39.6%
TLSA Tiziana Life Sciences	Jul 22, 2025	BUY	Strong Buy +489.2% avg upside 5 analysts	$8.00 589.59% Upside	-13.0%
BTAI Bioxcel Therapeutics	Jul 15, 2025	BUY	Buy +1933.0% avg upside 12 analysts	—	-36.3%
MGTX Meiragtx Holdings	Jun 09, 2025	BUY	Strong Buy +130.8% avg upside 13 analysts	$50.00 341.61% Upside	+45.7%
ATAI Atai Beckley N.V.	Jun 06, 2025	BUY	Strong Buy +230.1% avg upside 16 analysts	$12.00 195.50% Upside	+66.4%
HELP Helus Pharma	Jun 06, 2025	BUY	Strong Buy +861.2% avg upside 12 analysts	$106.00 2169.90% Upside	·
FBRX Forte Biosciences	Jun 05, 2025	BUY	Strong Buy +128.0% avg upside 14 analysts	$28.00 56.85% Upside	+123.3%
MNPR Monopar Therapeutics Inc	Jun 05, 2025	BUY	Strong Buy +46.7% avg upside 18 analysts	$71.00 5.25% Upside	+55.9%
UNCY Unicycive Therapeutics	Jun 04, 2025	BUY	Strong Buy +708.7% avg upside 10 analysts	$120.00 1651.75% Upside	+4.3%
TELO Telomir Pharmaceuticals, Inc.	Feb 20, 2025	BUY	Strong Buy +748.2% avg upside 2 analysts	$15.00 956.33% Upside	-72.7%
GHRS GH Research	Feb 07, 2025	BUY	Strong Buy +64.5% avg upside 11 analysts	$36.00 61.91% Upside	+9.3%
CMPS COMPASS Pathways	Jan 27, 2025	BUY	Strong Buy +63.7% avg upside 18 analysts	$9.00 28.15% Downside	+93.6%
FBLG FibroBiologics, Inc.	Dec 11, 2024	BUY	Buy +1198.3% avg upside 4 analysts	$12.00 1457.98% Upside	-84.8%
CNTN Canton Strategic Holdings	Dec 06, 2024	BUY	Strong Buy +1273.2% avg upside 3 analysts	$17.00 407.50% Upside	·
ANRO Alto Neuroscience, Inc.	Oct 23, 2024	HOLD	Strong Buy +33.3% avg upside 13 analysts	$5.50 75.91% Downside	+156.4%
MIRA MIRA Pharmaceuticals, Inc.	Sep 30, 2024	BUY	Strong Buy +1201.4% avg upside 2 analysts	$17.00 1685.02% Upside	+4.6%
LONA LeonaBio	Sep 04, 2024	HOLD	Buy +13.9% avg upside 9 analysts	$0.75 90.91% Downside	-36.7%
ANVS Annovis Bio	Jul 02, 2024	BUY	Strong Buy +1309.5% avg upside 7 analysts	$67.00 3728.56% Upside	-74.4%
CGTX Cognition Therapeutics	Jun 13, 2024	BUY	Strong Buy +305.1% avg upside 9 analysts	$14.00 865.45% Upside	-38.7%
SCLX Scilex Holding Company	Jun 12, 2024	BUY	Strong Buy +4351.2% avg upside 5 analysts	$455.00 5991.07% Upside	-89.7%
DFTX Definium Therapeutics	Apr 04, 2024	BUY	Strong Buy +45.0% avg upside 20 analysts	$28.00 14.37% Upside	-49.7%
RKTO Rocket One	May 31, 2023	BUY	Strong Buy +905.3% avg upside 8 analysts	$14.00 1196.29% Upside	·
KTTA Pasithea Therapeutics Corp	May 31, 2023	BUY	Strong Buy +2919.9% avg upside 3 analysts	$40.00 7899.91% Upside	-22.0%
BBLG Bone Biologics	May 31, 2023	BUY	Strong Buy +4523.2% avg upside 2 analysts	$67.50 4523.19% Upside	·
CLNN Clene	Mar 08, 2023	BUY	Strong Buy +442.4% avg upside 11 analysts	$13.00 116.39% Upside	-61.5%
DMAC Diamedica Therapeutics	Oct 27, 2021	BUY	Strong Buy +153.7% avg upside 12 analysts	$24.00 310.28% Upside	-69.7%
CRBP Corbus Pharmaceuticals	Mar 15, 2021	HOLD	Strong Buy +338.6% avg upside 20 analysts	$1.79 78.33% Downside	-83.3%
ARCT Arcturus Therapeutics	Mar 02, 2021	SELL	Buy +291.8% avg upside 35 analysts	$45.00 497.67% Upside	+59.2%
DARE Daré Bioscience	Jan 11, 2021	BUY	Strong Buy +516.8% avg upside 14 analysts	$9.00 314.80% Upside	+32.3%
HEPA Hepion Pharmaceuticals	Dec 01, 2020	BUY	Strong Buy +82042.8% avg upside 9 analysts	$8.00 13233.24% Upside	·
MESO Mesoblast	Sep 10, 2019	BUY	Strong Buy +73.3% avg upside 14 analysts	$23.00 60.15% Upside	+163.2%
ABEO Abeona Therapeutics	Aug 12, 2019	HOLD	Strong Buy +196.6% avg upside 17 analysts	$2.00 65.30% Downside	+27.6%
QURE uniQure	Jul 08, 2019	BUY	Strong Buy +16.1% avg upside 29 analysts	$94.00 103.01% Upside	-36.8%
ARWR Arrowhead Pharmaceuticals	Jun 27, 2019	HOLD	Strong Buy -19.1% avg upside 26 analysts	$24.00 70.75% Downside	+50.1%
ALDX Aldeyra Therapeutics	Jun 25, 2019	BUY	Strong Buy +716.1% avg upside 21 analysts	$33.00 1583.76% Upside	-32.5%
KRYS Krystal Biotech	Jun 24, 2019	BUY	Strong Buy -28.3% avg upside 19 analysts	$67.00 80.85% Downside	+4.1%
MBIO Mustang Bio	Jun 20, 2019	BUY	Strong Buy +905.8% avg upside 5 analysts	$7.00 976.83% Upside	-4.2%
RIGL Rigel	May 07, 2019	BUY	Strong Buy -27.5% avg upside 17 analysts	$7.00 78.68% Downside	-21.1%
GLMD Galmed Pharmaceuticals	May 07, 2019	BUY	Buy +4115.6% avg upside 13 analysts	$59.00 10072.47% Upside	-38.3%
AUPH Aurinia Pharmaceuticals	Mar 19, 2019	BUY	Strong Buy -7.1% avg upside 12 analysts	$24.00 45.80% Upside	+79.6%
OCUL Ocular Therapeutix	Mar 07, 2019	BUY	Strong Buy +159.5% avg upside 21 analysts	$24.00 154.41% Upside	+57.8%
GKOS Glaukos	May 04, 2018	HOLD	Strong Buy +5.9% avg upside 20 analysts	—	+118.8%
OMER Omeros	Mar 01, 2018	HOLD	Buy +111.5% avg upside 14 analysts	$19.00 84.78% Upside	+54.3%
PVLA Palvella Therapeutics	Mar 23, 2016	BUY	Strong Buy +45.4% avg upside 27 analysts	$7.00 93.87% Downside	·
GALT Galectin Therapeutics	Mar 09, 2016	BUY	Strong Buy +245.1% avg upside 8 analysts	—	+27.3%
ANIP ANI Pharmaceuticals	Feb 15, 2012	HOLD	Strong Buy +28.6% avg upside 11 analysts	—	-76.3%

🔒 56 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Elemer Piros — Frequently Asked Questions

How accurate are Elemer Piros's stock ratings?

Based on the calls 13Foresight could measure, about 44% of Elemer's ratings were profitable over a one-year hold, with an average return of +6.8% per rating, or -6.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Elemer ranked on 13Foresight?

Elemer Piros is currently ranked #2416 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Elemer cover?

Elemer most recently has ratings on ADIL, NRXP, XOMA, PASG, NGEN, OCGN, INMB, QNCX, MNOV, VTGN, CH:NWRN, NEUP and 49 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!